Esosan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esosan

What is Esosan? (Overview)

Property Description
Active ingredient Esomeprazole (INN)
Form Delayed-release capsules, gastro-resistant tablets, injection solution
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid secretion
Origin Synthetic compound (Benzimidazole derivative)

What Type of Medicine is Esosan?

Esosan is a pharmaceutical preparation containing the active substance Esomeprazole, which belongs to the definitive drug class known as Proton Pump Inhibitors (PPIs). PPIs are a group of synthetic compounds designed for effective control over gastric acid production. This classification indicates that the medicine functions by directly targeting the specialized enzyme system responsible for acid secretion in the stomach.

As a single-ingredient product, Esomeprazole is structurally classified as a benzimidazole derivative. It is notable for being the purified S-isomer of Omeprazole, its close predecessor, a refinement in chemical identity that is recognized for contributing to its consistent action within the body. The general purpose of Esosan, therefore, is to create an environment of significantly lowered acidity in the upper gastrointestinal tract.

Composition and Physical Form

The core component of the preparation is Esomeprazole, typically presented as a salt, such as Esomeprazole Magnesium or Esomeprazole Sodium. Esosan is available in multiple high-level forms, including delayed-release capsules and gastro-resistant tablets for oral use, and a lyophilized powder for the preparation of an intravenous injection solution. The specialized oral dosage forms are engineered to be gastro-resistant, a design feature ensuring the acid-sensitive active ingredient is protected from degradation as it passes through the stomach. This protection facilitates proper systemic absorption into the bloodstream, allowing the medicine to reach its target.

Esosan's General Purpose

The overarching functional benefit of Esosan is the profound and sustained reduction of gastric acid secretion. By effectively neutralizing the primary mechanism of acid production, the medicine fundamentally alters the environment within the stomach and esophagus. This action serves the general therapeutic purpose of mitigating the destructive effects of highly corrosive acid and fostering a state of physiological relief.

Regulatory References

  1. U.S. National Library of Medicine
  2. NIH MedlinePlus: Esomeprazole

What side effects are possible with Esosan?

Possible Side Effects and Safety Information

The safety profile of Esosan (Esomeprazole) is derived from extensive clinical data and regulatory monitoring, structuring potential adverse effects by both the body system affected and their reported frequency, consistent with official government documents.

Frequency-Classified Adverse Reactions

The most common reactions, which may affect up to 1 in 10 people, include headache and gastrointestinal disturbances such as diarrhea, abdominal pain, constipation, nausea, and vomiting. Uncommon effects are reported less frequently and may include dizziness, dry mouth, or skin manifestations like rash and itching.

Classification Examples of Officially Listed Reactions
Rare Serious hypersensitivity reactions, leukopenia (low white cell count), hyponatraemia (low sodium), confusion, hepatitis
Very Rare Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS); interstitial nephritis; hepatic failure
Not Known Hypomagnesaemia (low magnesium), microscopic colitis, fundic gland polyps (associated with long-term use)

Serious Safety Considerations

Regulatory documentation highlights the potential for rare, but serious, adverse reactions, including anaphylactic shock and other severe allergic manifestations. Certain risks are specifically associated with the duration of use: long-term therapy (typically over one year) has been officially linked to an increased risk of bone fractures of the hip, wrist, or spine, and the formation of benign fundic gland polyps.

Population-Specific Notes

Specific caution is advised for patients with severe hepatic impairment, with some regulatory labels recommending that the daily dose should not exceed 20 mg due to potential increases in drug exposure. Esosan is generally contraindicated in individuals with known hypersensitivity to the active substance, Esomeprazole, or its structural drug class.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations of Esosan (Esomeprazole) overdose and the regulator-mandated emergency actions.

Documented Overdose Manifestations

The clinical signs of overdose documented in official prescribing information may include a range of manifestations affecting the central and autonomic nervous systems. These reported signs include confusion, blurred vision, drowsiness, and an unusually fast heart rate. Additionally, extreme sweating, dry mouth, nausea, and headache have been noted in cases of over-exposure.

Official Emergency Actions

Official regulatory guidance requires specific, immediate actions in the event of a suspected overdose:

  • Poison Control Contact: You must contact a Poison Control Center right away for consultation and advice regarding the management of the over-exposure.
  • Emergency Services: Immediate medical help (e.g., calling 911 or the local emergency number) is required if the affected individual develops severe symptoms, such as passing out or experiencing trouble breathing.

Management and Antidote Status

Regulatory documents state that there is no specific antidote known for Esomeprazole overdose. Management is therefore limited to symptomatic and supportive treatment provided in a professional medical setting. Professional assessment and monitoring are mandatory following any suspected overdose.

Therapeutic Uses of Esosan

What Esosan Treats: Main Uses and Benefits

Esosan is typically used to help manage symptoms associated with certain acid-related conditions. The clinical scenarios of use commonly include addressing the symptoms of gastroesophageal reflux disease (GERD), supporting the management of damage to the esophagus related to GERD, and assisting in reducing the risk of stomach ulcers in patients using nonsteroidal anti-inflammatory drugs (NSAIDs). It is also used in combination with other medications to address ulcers potentially associated with H. pylori bacteria, and to manage conditions where there is excess acid production, such as Zollinger-Ellison syndrome.

Esosan is designed to address discomfort like heartburn and supports the body's natural processes related to damaged tissue, such as the esophagus lining. The patient may experience a reduction in painful symptoms and support for managing the condition's progression.

Relief from frequent, bothersome symptoms is among the benefits sought by patients. This information reflects established medical guidance regarding approved therapeutic domains.


Quick Fact: Symptom Relief for GERD

Eligibility and Restrictions for Use

Esosan's eligibility is strictly defined by regulatory authorities and centers on absolute contraindications, patient age, and the status of certain pre-existing conditions.

Who Must Not Use Esosan (Contraindications)

  • Hypersensitivity: The medicine is strictly contraindicated for patients with a known allergy to the active substance, esomeprazole, or to any other drug in the benzimidazole class (e.g., omeprazole).
  • Nelfinavir Therapy: Esosan must not be used concurrently by patients taking the antiretroviral drug nelfinavir, as mandated in official labeling due to significant reduction in the effectiveness of nelfinavir.

Eligibility by Population and Age

Population Group Official Eligibility Status
Adults ( 18 years) Fully approved for all labeled uses.
Pediatric Patients Approved for specific uses in children and adolescents, down to a minimum age of one month.
Infants ( < 1 month) Safety and effectiveness are not established in this age group.
Older Adults ( 65 years) Approved; no general dose adjustment is required.

Condition-Based Restrictions

Use is allowed, but restricted or requires caution, in the following populations:

  • Severe Hepatic Impairment: Patients with severe liver impairment (Child-Pugh Class C) are limited to a mandated maximum daily dose for certain indications.
  • Renal Impairment: No routine dose adjustment is generally required, but caution is advised in cases of severe renal insufficiency due to limited clinical experience.

Pregnancy and Lactation Status

  • Pregnancy: Use is generally limited to situations where the expected therapeutic benefit clearly outweighs potential risks, as determined by a healthcare professional.
  • Lactation: Use is typically not recommended, as it is unknown if Esosan is excreted in human breast milk.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The following summary outlines the officially documented interaction patterns for Esosan (esomeprazole), based strictly on regulatory prescribing information.

Contraindicated and Restricted Combinations

Co-administration with specific antiretroviral agents is prohibited by regulatory authorities due to the risk of significantly decreased plasma levels of the antiviral medication. This includes Nelfinavir and products containing Rilpivirine. Additionally, the co-administration of Esosan with Clopidogrel should be avoided, as regulatory documents indicate it can decrease the formation of the active metabolite of Clopidogrel.

Interaction-Related Changes in Drug Exposure

Esosan alters the pH environment of the stomach, which changes the absorption of co-administered drugs. Medicines that rely on an acidic environment, such as Ketoconazole and Erlotinib, may have decreased absorption, while the absorption of Digoxin is documented to increase. Furthermore, Esosan acts as an inhibitor of the CYP2C19 enzyme, potentially raising the concentration of medicines metabolized by this pathway, including Phenytoin and Warfarin. Increased serum levels requiring monitoring have also been documented with Methotrexate and Tacrolimus.

Other Interaction Constraints

The official label requires that Esosan be temporarily discontinued before certain diagnostic investigations for neuroendocrine tumors, as its effect on the stomach's pH can interfere with the measurement of Chromogranin A (CgA) levels. The herbal product St. John's Wort is also listed as an agent whose concomitant use should be avoided due to the potential for reduced Esosan plasma concentrations.

Mechanism of Action

Molecular-Level Enzyme Inhibition

This domain covers Esosan's direct action on the H^+/ K^+ ATPase enzyme, commonly known as the gastric proton pump, located in the parietal cells of the stomach lining.

Esosan, an S-isomer, acts as a prodrug that is selectively concentrated and activated in the acidic secretory canaliculi of the parietal cell. Once active, it forms a covalent bond with specific cysteine residues on the exposed proton pump. This irreversible binding represents the interaction type, effectively blocking the final step in the acid secretion process and initiating a mechanistic cascade that suppresses signaling sequences that drive hydrogen ion ( H^+) efflux.


Pathway Modulation and Systemic Effect

The irreversible inhibition of the proton pumps leads to a profound and long-lasting reduction in gastric acid secretion regardless of the physiological stimulus. This effect represents the system-level physiological consequence. The persistence of the reduction is determined by the half-life of the pump protein itself, as new enzyme synthesis is required to restore full acid output. This mechanism results in prolonged physiological modulation of gastric pH, thereby sustaining an elevated intragastric pH throughout the digestive system.

Dosage and Administration Information

How to Use Esosan

Esosan (Esomeprazole) is administered via the oral route for standard treatment and maintenance, and via the intravenous (IV) route for specific acute clinical scenarios. Its use is defined by precise dosing, frequency, and administration conditions.


Official Administration Routes and Forms

Route Forms and Strengths
Oral Delayed-release capsules/tablets: 20 mg and 40 mg. Also available as oral suspension packets.
Intravenous Lyophilized powder for injection: 20 mg or 40 mg per vial.

Standard Dosing Patterns and Timing

For most approved indications, the medicine is administered once daily in doses of 20 mg or 40 mg. Oral forms must be taken at least one hour before a meal to ensure the gastro-resistant coating is not compromised before reaching the intended absorption site.

For certain conditions, such as pathological hypersecretory states, the dose may be increased and administered twice daily. The total duration of use varies, typically ranging from 4 to 8 weeks for healing, or up to 6 months for maintenance of healed erosive conditions.

The specialized oral forms must not be crushed or chewed to preserve the integrity of the delayed-release formulation. In cases of severe hepatic impairment, the maximum daily oral dose generally should not exceed 20 mg. Intravenous therapy, which may involve an 80 mg loading dose followed by a continuous infusion, is restricted to short-term use only and is intended to be followed by oral therapy to complete the full treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esosan

Clinical data for Esosan (esomeprazole) primarily comes from Randomized Controlled Trials (RCTs), which are studies that compare the medicine against a placebo (inactive substance) or other therapies. This overview describes what the research has explored and what patterns have been observed so far, focusing only on the official research record.


Evidence for use in Managing Symptoms of GERD

RCTs were used in research exploring symptomatic Gastroesophageal Reflux Disease (GERD). The research examined individuals with conditions characterized by fluctuating or episodic manifestations of reflux. Findings describe patterns where changes in symptom reporting were documented during the study intervals when compared to groups receiving an inactive substance. Reports indicate that results apply only to the populations studied, and that individual responses may vary.

Evidence for Healing and Preventing Esophageal Damage

Research explored Erosive Esophagitis (EE), a condition characterized by damage to the esophagus. Acute healing trials were typically short-term RCTs, and the primary measure was the endoscopic healing rate. Maintenance trials monitored the rate of relapse, or return, of the esophageal damage. Studies reported patterns of change in endoscopic assessments when compared to placebo. The clinical interpretation of outcomes compared to other therapies is subject to discussion in broader scientific reviews.

Evidence for Combination Use in H. pylori and Ulcer Management

Esosan was evaluated in studies as part of a multi-drug regimen for the eradication of Helicobacter pylori. Studies reported that when the medicine was combined with specific antibiotics, measurements related to H. pylori clearance were frequently documented. Separately, for NSAID-related ulcer research, studies reported patterns of change in observed ulcer status and the documentation of fewer incident ulcer events over periods up to six months. The comparative evidence is lacking in large-scale studies that assess Esosan against other PPIs when both are used in equivalent doses.

Research Gaps and Areas of Uncertainty

Data for certain groups remain insufficient, especially regarding the long-term use of the medicine in children and adolescents. Due to the rarity of conditions like Zollinger-Ellison Syndrome (ZES), evidence comes from long-term, uncontrolled observational settings. The research provides context, but findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the results reported in trials.

Key Studies & References NIH MedlinePlus Drug Information: Esomeprazole

Frequently Asked Questions (FAQ)

Common questions about Esosan (FAQ)


Q: What should I know about Esosan before starting it?

Official regulatory documents indicate that Esosan is approved for conditions such as the treatment of GERD, the healing of erosive esophagitis, and the reduction of the risk of NSAID-associated gastric ulcers. Official documents state it is contraindicated in patients with known hypersensitivity to the drug or to any substituted benzimidazoles.


Q: Are there any long-term effects of using Esosan?

Studies and official safety information indicate that the long-term use of medicines in this class (PPIs) may be associated with increased documented risks. These documented risks include bone fracture, a form of diarrhea known as Clostridium difficile-associated diarrhea, and Vitamin B12 deficiency.


Q: Can older adults use Esosan safely?

According to the official product information, appropriate studies have not shown unique problems in older adults that would limit the use of Esosan. However, in older patients who have a suboptimal response to therapy, regulatory documents may recommend considering further testing, such as an endoscopy.


Q: When is the best time of day to take Esosan for the intended use?

For most approved conditions, Esosan is generally taken once daily. Regulatory guidance describes that it is often taken in the morning, which is in addition to the rule that the oral form must be taken at least one hour before a meal.


Q: What if I already have other medical conditions?

Caution is described in regulatory documents for patients with severe liver or kidney problems. Additionally, specific warnings exist for individuals with a history of low magnesium levels (hypomagnesemia), osteoporosis, or Vitamin B12 deficiency.


Q: Are there specific foods or drinks to avoid while taking Esosan?

Regulatory information does not generally list specific foods or drinks to avoid, but it strongly emphasizes timing. The delayed-release oral form must be swallowed whole, and should be taken at least one hour before a meal to ensure the medicine works as intended.


Q: How long does it typically take to start noticing a change with Esosan?

The official product information indicates that the onset of the acid-reducing effect after taking an oral dose occurs within one hour. The sustained reduction in acid allows the treatment and healing process to begin.


Q: What happens if I miss a day of Esosan?

Patient instructions describe a process where a missed daily dose may be taken as soon as remembered, unless it is close to the next scheduled dose. In such cases, the missed dose is skipped. In regulatory guidance, individuals are typically advised not to take a double dose.


Q: Is it okay to take Esosan with a multivitamin?

Medicines like Esosan may affect the absorption of certain vitamins and minerals. The regulatory label specifically notes that daily use for longer than three years may be associated with a deficiency of Vitamin B12 (Cyanocobalamin). For this reason, some form of monitoring may be necessary during long-term use.


Q: Can Esosan cause trouble sleeping?

Trouble sleeping or somnolence (drowsiness) is listed as an adverse reaction in the regulatory documents. This effect is described as common in clinical trials involving pediatric patients (ages 1 to 17).


Q: Does Esosan affect blood pressure?

While not a common adverse reaction reported in clinical trials, serious heart or cardiovascular events are sometimes reported in post-marketing surveillance data for medicines in the PPI class.


Q: Why do some people say Esosan makes them feel tired?

Fatigue or somnolence (drowsiness) is listed as a potential adverse reaction in the official product information. This effect is noted as a common occurrence in pediatric patients (ages 1 to 17) who took the medicine in clinical studies.


Q: What are the most common reasons people stop taking Esosan?

Clinical trial data describes the most common adverse reactions that have been associated with discontinuation of Esosan, which include abdominal pain, headache, diarrhea, and nausea. Other common gastrointestinal effects include flatulence, dry mouth, and constipation.


Q: Can I take pain relievers like ibuprofen while on Esosan?

Esosan is approved for an indication to help reduce the risk of gastric ulcers associated with the continuous use of pain relievers in the NSAID class (like Ibuprofen). The regulatory label shows no specific clinically significant interaction with ibuprofen itself.


Q: Can Esosan impact how well birth control works?

Official product information suggests that Esosan is generally not expected to cause clinically relevant interactions with oral contraceptives. This is because the drug is not likely to inhibit the liver enzymes responsible for metabolizing most forms of birth control.


Q: Does Esosan have an effect on weight?

Significant unintentional weight loss is described in regulatory labels as an 'alarm symptom' that warrants further follow-up before and during treatment. Changes in weight (gain or loss) are not typically listed as a common side effect.


Q: What is the official purpose of Esosan, according to the FDA?

The FDA's official indications for Esosan include treating Gastroesophageal Reflux Disease (GERD), reducing the risk of ulcers from NSAID use, the eradication of H. pylori, and treating specific pathological hypersecretory conditions like Zollinger-Ellison Syndrome.


Q: Are there any known interactions between Esosan and herbal supplements?

Official regulatory labels advise avoiding concomitant use (taking together) of Esosan with the herbal remedy St. John’s Wort (Hypericum perforatum). This is because St. John's Wort may cause a significant decrease in the amount of Esosan in the blood, potentially making it less effective.


Q: Is Esosan considered a new or older medication?

The medicine Esosan (esomeprazole) is considered a well-established medication. Its original brand formulation was first approved by the FDA in 2001, and it is now also widely available as a generic.


Q: How is the research evidence for Esosan described in official documents?

Official regulatory documents contain sections summarizing the clinical evidence and research. These sections detail clinical trials that examined the healing of erosive esophagitis, the relief of symptomatic GERD, and the risk reduction of NSAID-associated ulcers.


Q: Does Esosan require any special monitoring while using it?

Depending on the duration of use and other medications being taken, specific monitoring may be needed. This includes checking Vitamin B12 or serum magnesium levels in long-term patients, and monitoring if it is used together with certain blood thinners like warfarin.


Q: Can children or teenagers use Esosan?

Yes, Esosan is approved for use in certain pediatric patients, including those ages 1 to 17, for specific indications such as GERD. Regulatory documents provide weight- and age-based guidance for its use in these populations.


Q: What if I experience mild nausea while taking Esosan?

Official safety data lists nausea as a common adverse reaction that has occurred in clinical trials (ge 1% in adults and ge 2% in pediatric patients). Regulatory principles emphasize the importance of discussing any persistent or concerning symptoms with a healthcare provider.


Q: Is it safe to drive or operate machinery while using Esosan?

Official product information notes that, while uncommon, certain adverse effects such as dizziness, visual disturbances, or drowsiness may occur. If a patient experiences these effects, their ability to drive or operate machinery could be impaired.


Q: What does the term 'contraindication' mean for Esosan?

A contraindication refers to a condition under which the drug should absolutely not be used because the risks outweigh any potential benefits. For Esosan, a primary contraindication is a known hypersensitivity or severe allergic reaction to the drug or related compounds.


Q: Does taking Esosan change how I feel emotionally?

While rare, psychiatric events are mentioned in post-marketing reports (meaning they occurred after the drug was approved and put on the market). These reports have included symptoms such as depression, aggression, and hallucinations.


Q: Is there a generic version of Esosan available?

Yes, the active ingredient, esomeprazole, is available as a generic medication. Regulatory systems ensure that generic versions contain the same active ingredient, strength, and quality standards as the brand name product.


Q: Do many people experience the more serious side effects of Esosan?

Serious adverse reactions are reported through post-marketing experience, indicating that while they are rare, they have occurred. These serious events include conditions like acute interstitial nephritis (a kidney reaction) or severe cutaneous adverse reactions (SCARs), which are severe skin reactions.


Q: Can Esosan be taken with a cold or flu medicine?

The regulatory label notes that a clinically relevant interaction is generally not expected with many common drug types. However, regulatory information identifies specific serious interactions, such as with methotrexate or clopidogrel.


Q: Are there any ingredients in Esosan that commonly cause allergies?

Esosan is contraindicated if a person has a known hypersensitivity to the drug itself or to other medicines in the same chemical class, known as substituted benzimidazoles. An allergic reaction is a primary reason not to use the medicine.


Q: Can Esosan cause my heart to race?

Though not a common event, serious cardiovascular events have been reported during post-marketing surveillance for the medicine class. This includes reports of abnormal heart rhythms (arrhythmias) or a rapid heart rate.


Q: Is Esosan safe to use during the summer/in hot weather?

The regulatory label describes that the drug should be maintained at a specific controlled room temperature to ensure its integrity and stability. This is a necessary consideration for maintaining the integrity of the medicine.


Q: What research is available about Esosan's use in diverse populations?

Official regulatory documents include sections detailing the drug's use in various clinical settings. This includes information on geriatric, pediatric, and renally or hepatically impaired populations to support its use in diverse groups of patients.


Q: Is the onset of action for Esosan fast or slow?

Official pharmacodynamic data shows that the initial acid-reducing effect of the medicine begins relatively quickly, occurring within one hour after the oral dose is administered.


Q: What are the official warnings associated with Esosan?

Official warnings and precautions from regulatory sources include the risks of gastric malignancy, C. difficile-associated diarrhea, and the risk of bone fracture and Vitamin B12 deficiency with long-term use.


Q: Can Esosan be taken with alcohol (informational description only)?

Regulatory documents do not typically list alcohol as a direct drug interaction. However, because Esosan is often used to treat or prevent gastrointestinal issues, it is worth noting that alcohol use is frequently cited as a risk factor for GI bleeding or ulcers.


Q: Is Esosan a prescription-only medicine?

Esosan (esomeprazole) is available in some formulations as a prescription-only (Rx) medicine. However, in lower strengths and smaller pack sizes, it is also available as a non-prescription (OTC) medicine in some jurisdictions.


Q: How is Esosan different from a placebo in studies?

Clinical study summaries included in regulatory documents show that Esosan demonstrated a statistically significant difference in efficacy compared to a placebo. This difference is documented across various study endpoints, such as the healing rate of esophagitis and symptomatic relief.


Q: Is it common to have headaches when first starting Esosan?

Headache is listed as one of the most common adverse reactions reported in clinical trials. It was documented in adults at a rate of ge 1% and in pediatric patients at a rate of ge 2%.


Q: What should I do if I am traveling and forget my Esosan?

Practical instructions for a missed dose describe that if a daily dose is forgotten, it may be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose is skipped entirely to avoid taking too much.


Q: Do I need to stop taking Esosan gradually?

For individuals who have been taking Esosan for a long time, stopping the medicine suddenly may lead to a temporary return of high acid levels, sometimes called rebound acid production. Official regulatory guidance suggests that patients should consult their doctor before discontinuing long-term use.


Q: What is the difference between the brand name and generic Esosan?

The generic version of Esosan contains the same active ingredient (esomeprazole) in the same strength and dosage form. It must meet the same rigorous quality standards as the brand name product to receive regulatory approval.


Q: Is Esosan related to any other well-known drug classes?

Yes, Esosan is chemically classified as a Proton Pump Inhibitor (PPI). This class of medicine is known for its action of blocking the final step of acid production in the stomach.


Q: How is Esosan processed by the body?

Regulatory documents on pharmacokinetics describe that Esosan is largely processed in the liver by specific enzyme systems, mainly CYP2C19 and CYP3A4. After processing, the inactive substances are then primarily eliminated from the body through the urine.

How should Esosan be stored and disposed of?

How to Store and Dispose of Esosan

Official regulatory documents define strict requirements for the storage and disposal of Esosan to maintain its quality and prevent environmental contamination. All storage instructions are based on government labeling to ensure product stability.

Official Storage and Handling

Requirement Details from Regulatory Labeling
Temperature Store below 30 C. Do not store above the stated maximum temperature.
Protection Must be protected from light, heat, and moisture. Store in a dry place.
Packaging Keep the medicine in its original, well-closed container until use.
Child Safety Store Esosan out of the reach and sight of children.

Official Disposal Protocol

To dispose of expired or unused Esosan, follow the guidance provided in the official labeling to ensure environmental compliance. The medicine must not be disposed of via household trash, down a sink, or into a toilet. Instead, dispose of the product according to your national and local pharmaceutical waste collection regulations, such as collection points or pharmacy take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Esosan found in:

A-Z Index: